Browse the evidence

Self-reported increases in sweet and salty taste perception during GLP-1 or dual GIP/GLP-1 receptor agonist therapy are significantly associated with increased satiety, reduced appetite, and reduced food craving.

If you are taking a GLP-1 medication and notice your taste has changed (e.g., sweets taste stronger or saltier), this is a common and potentially helpful side effect. The research suggests these sensory changes are linked to feeling fuller faster and having fewer cravings, which supports your weight loss efforts. Do not be alarmed by these changes; they may be part of how the medication helps regulate your appetite.

Reducing the dosing frequency of GLP-1 receptor agonists (semaglutide and tirzepatide) after initial weight loss maintenance preserves a significant proportion of weight loss efficacy compared to once-weekly dosing, making it a viable strategy for long-term weight maintenance.

If you are maintaining weight loss on a GLP-1 agonist (like semaglutide or tirzepatide) and face supply issues or high costs, discuss extending the dosing interval with your provider. Instead of stopping completely, moving from weekly to every 10-14 days (or even 28 days for some) can maintain a significant portion of your weight loss (e.g., 50-70%) while saving money and extending supply. This is not a substitute for lifestyle changes but a viable maintenance strategy.

In patients with mild to moderate Parkinson's disease, protein intake below 1 g/kg/day is independently associated with positive sarcopenia screening, higher fat mass index, and lower relative skeletal muscle index.

If you have mild to moderate Parkinson's, ensure you are eating at least 1 gram of protein per kilogram of body weight daily. This study links lower intake to loss of muscle strength and increased body fat. Talk to your doctor about timing your protein intake around your medication to maximize both drug effectiveness and muscle health.

Personalized behavioral weight loss (PBWL) involving a 4-week experimentation phase with continuous glucose monitoring (CGM) yields significantly greater 12-week weight loss than standard behavioral weight loss (BWL) with fixed prescriptions.

Instead of sticking to one diet, try a 4-week 'experiment' phase. Use a continuous glucose monitor (CGM) to test different macronutrient ratios (low-carb vs. low-fat) and meal frequencies (3 meals vs. snacks). Track how your blood sugar and hunger respond to each. After 4 weeks, pick the combination that gave you the best glucose control and felt most sustainable, then stick with it for the next 8 weeks. This personalized approach led to nearly double the weight loss of standard dieting in this study.

GLP-1 receptor agonists (semaglutide, liraglutide) reduce binge eating episodes and food cravings in Binge Eating Disorder by modulating mesolimbic dopamine signaling and hypothalamic satiety pathways.

If you struggle with binge eating, current talk therapies may not be enough for long-term control. GLP-1 medications like semaglutide or liraglutide are showing promise in reducing the compulsive drive to binge by targeting brain reward circuits. While not yet a standard cure, they offer a biological lever to complement therapy. Discuss with a doctor if you have BED, as small trials show significant symptom reduction.

In patients with type 2 diabetes, subcutaneous semaglutide produces superior long-term weight loss compared to oral semaglutide over a two-year period.

If you have Type 2 Diabetes and are using semaglutide for weight loss, the injection form is significantly more effective than the pill form over the long term (2 years). You will likely lose more weight and have a higher chance of losing 10% or more of your body weight with the injection. However, if you are over 65, the oral pill might offer weight loss results similar to the injection, making it a viable alternative if you want to avoid needles.

Genetic variants in the FTO gene increase obesity susceptibility, but this genetic risk can be reduced by approximately 30% through engagement in physical activity.

If you have a family history of obesity, do not assume you are destined to gain weight. Research shows that regular physical activity can significantly blunt the impact of common obesity genes (like FTO). Prioritize consistent exercise as a primary tool to manage your genetic risk.

Polygenic risk scores (PRS) and genetic risk scores (GRS) can identify individuals with high genetic susceptibility to obesity, allowing for targeted preventative interventions.

While PRS can identify high-risk individuals, current scores are not precise enough for individual clinical decision-making for most people. Focus on standard healthy lifestyle habits regardless of genetic testing results.

A short-term (7-week) supervised intervention of Time-Restricted Eating (TRE) and/or High-Intensity Interval Training (HIIT) can promote long-term self-reported maintenance of these lifestyle behaviors in women with overweight/obesity, with approximately 45-46% continuing the respective interventions two years later without ongoing supervision.

If you are overweight or obese, a short, supervised period of Time-Restricted Eating (limiting eating to 10 hours a day) or High-Intensity Interval Training (3 sessions a week) can help you build the habit to continue these behaviors on your own for years. You don't need to be perfect; maintaining the habit 5 days a week is sufficient for long-term success. The key is using the initial supervised time to learn how to fit these flexible strategies into your real life, rather than relying on constant external motivation.

Semaglutide 2.4 mg facilitates substantial, sustainable weight loss and improves cardiometabolic health by reducing 'food noise' and maladaptive eating behaviors.

Semaglutide 2.4 mg is an effective tool for reducing 'food noise' and enabling sustainable weight loss when lifestyle changes alone are insufficient. It works by altering hormonal signals related to appetite and satiety.

GLP-1RAs reduce emotional eating in the short term (3-6 months) by modulating reward processing, but this effect may not be long-lasting (12 months) and does not address underlying emotion regulation deficits.

GLP-1RAs like semaglutide can help reduce emotional eating for the first 3-6 months by changing how your brain responds to food rewards. However, this effect may fade after a year, and the medication does not fix the underlying emotional regulation skills. For lasting results, combine GLP-1RA treatment with emotion regulation therapies like CBT or DBT.

GLP-1 receptor agonists (e.g., semaglutide) and dual/triple agonists (e.g., tirzepatide) cause significant lean body mass loss (up to 40% of total weight loss), but this largely reflects reductions in non-contractile organs (liver, kidneys) rather than true skeletal muscle atrophy, with functional strength often preserved or improved.

If you are taking a GLP-1 drug like semaglutide, expect your total 'lean mass' number to drop significantly (up to 40% of weight lost). However, this is mostly water and organ mass (liver/kidneys), not your actual muscle fibers. Your strength likely stays the same or gets better because you are lighter. Focus on resistance training to maintain muscle quality, but do not panic about 'muscle wasting' as the primary driver of weight loss.

A personalized ketogenic diet (≤20g carbs/day) induces rapid fat loss and preserves skeletal muscle mass in the short term (3 months), but long-term adherence drops significantly after the initial phase.

Start with a strict limit of 20g carbs daily, focusing on healthy fats and moderate protein. Expect rapid fat loss in the first 3 months, but be prepared for a drop-off in motivation. To stay on track, monitor ketones, manage electrolytes to avoid 'keto flu', and work with a professional to adjust calories if weight loss stalls.

Vitamin D supplementation can suppress myostatin expression and stimulate anabolic pathways (Akt/mTOR, IGF-1), potentially aiding muscle preservation in at-risk populations.

If you are elderly or have a chronic condition, ensuring adequate Vitamin D levels may help support muscle health by influencing myostatin and anabolic pathways. Consult your doctor for appropriate dosing, as thresholds are not yet defined.

Structured lifestyle counseling in primary care significantly improves patient outcomes, including reduced stress, enhanced treatment adherence, and better chronic disease management, by addressing psychosocial factors and promoting self-efficacy.

Integrate brief, structured lifestyle counseling into every primary care visit. Use established frameworks like the '5 A's' (Ask, Advise, Assess, Assist, Arrange) or 'FRAMES' to guide the interaction. Focus on shared decision-making and setting specific, measurable goals with the patient. Regularly monitor progress to adjust the plan. This approach improves adherence and chronic disease management without requiring extensive time or specialized therapy training.

Personalized nutrition improves postprandial glycemic response (PPGR) compared to control diets, with a median mean difference of -14.85 mg/dLxh.

Personalized nutrition significantly improves postprandial glycemic response (PPGR) compared to standard diets. This means blood sugar spikes after meals are better managed with personalized advice.

Higher consumption of ultraprocessed foods (UPFs) is positively associated with the prevalence of overall arthritis and specifically rheumatoid arthritis (RA) in U.S. adults, but not osteoarthritis (OA).

If you have arthritis or are at risk, reducing your intake of ultraprocessed foods (like sugary drinks, packaged snacks, and fast food) may help lower your risk of developing rheumatoid arthritis. This is because UPFs often drive inflammation and weight gain. You don't need to eliminate them entirely, but shifting your diet towards less processed options can have a measurable benefit.

GLP-1 agonist use (specifically semaglutide) is associated with a reduction in body mass index (from 34.1 ± 9 to 30.6 ± 6) and a decrease in smoking frequency/amount (by 14.4%) among users in Saudi Arabia.

If you are using GLP-1 agonists like semaglutide for weight loss, this study suggests you may also see a reduction in smoking frequency. However, be aware that cost and side effects are major reasons people stop taking the medication. To maintain weight loss, consistent use and healthy lifestyle habits (diet and exercise) are crucial, as obesity is a chronic condition requiring long-term management.

Early slow responders to bariatric surgery (low EWL at 3 months) should be identified through routine monitoring and offered intensified interventions, including pharmacologic support like GLP-1 receptor agonists.

If you are losing weight slower than expected in the first 3 months, talk to your doctor. You may be a 'slow responder,' and this is a known risk factor. Your team can offer extra support, such as dietary counseling, behavioral therapy, or medications like GLP-1 agonists, to help you get back on track.

Semaglutide treatment is associated with a 26% lower risk of fractures compared to sleeve gastrectomy in adults with obesity.

If you are at high risk for fractures (e.g., older age, diabetes, history of falls) and need to lose weight, discuss semaglutide with your provider. This study suggests it may be safer for your bones than sleeve gastrectomy, offering a 26% lower fracture risk in a large real-world cohort. However, because this is observational data, ensure you monitor your bone health and nutrition regardless of the chosen path.

Enobosarm (3-6 mg/day) preserves total lean mass and reduces fat mass loss when co-administered with semaglutide for weight loss in older adults with overweight/obesity, without compromising overall body weight reduction.

If you are taking semaglutide for weight loss and are concerned about losing muscle, ask your doctor about adding enobosarm (3-6 mg daily). Recent Phase 2b data suggests this combination preserves lean mass and increases fat loss compared to semaglutide alone, without changing total weight loss. Note that this specific combination is still under regulatory review and not yet approved.

GLP-1 receptor agonists (Liraglutide and Semaglutide) promote weight loss and modulate gut microbiota towards a lean-related profile, although clinical data on their specific impact on gut microbiota composition is currently limited.

GLP-1 agonists like Liraglutide and Semaglutide are effective pharmacological treatments for obesity, producing significant weight loss (approx. 6-8%) when combined with lifestyle changes. While they show promise in improving gut microbiota in animal studies, clinical data on these specific changes is still emerging.

In patients with overweight/obesity and established atherosclerotic cardiovascular disease (ASCVD), treatment with semaglutide 2.4 mg significantly reduces total annual medical costs and inpatient healthcare resource utilization compared to non-treated controls.

For patients with obesity and heart disease, using semaglutide 2.4 mg is associated with lower total medical bills over a year, primarily because it reduces the need for hospital stays. This suggests the drug can be cost-effective for this specific population by preventing expensive cardiovascular events.

GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) induce significant weight loss and modify inflammatory markers, suggesting potential oncological benefit, but high-quality data on cancer incidence is currently lacking.

GLP-1 agonists are effective for weight loss and may reduce cancer risk, but long-term cancer data is not yet available. They are a viable option for those who cannot undergo surgery.